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UPAR is a GPI anchored protein, which is found in both lipid rafts and in more fluid regions of the plasma membrane. We have studied the role
of the ligand uPA on uPAR localization and on the composition of the lipid membrane microdomains. We have analyzed the glycosphingolipid
environment of uPAR in detergent resistant membrane (DRM) fractions prepared by cell lysis with 1% Triton X-100 and fractionated by sucrose
gradient centrifugation obtained from HEK293-uPAR cells. The uPAR specific lipid membrane microdomain has been separated from the total
DRM fraction by immunoprecipitation with an anti-uPAR specific antibody under conditions that preserve membrane integrity. We have also
tested uPA-induced ERK phosphorylation in the presence of methyl-β-cyclodextrin, which is known to disrupt lipid rafts by sequestering
cholesterol from such domains. Our results show that uPAR is partially associated with DRM and this association is increased by ligands, is
independent of the catalytic activity of uPA, and is required for intracellular signalling. In the absence of ligands, uPAR experiences a lipid
environment very similar to that of total DRM, enriched in sphingomyelin and glycosphingolipids. However, after treatment of cells with uPA or
ATF the lipid environment is strongly impoverished of neutral glycosphingolipids.
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Extracellular proteolysis is a key element in diverse cellular
processes including cell adhesion, proliferation and migration.
These processes are involved in tissue remodelling, inflamma-
tion and tumour progression. The urokinase receptor (uPAR/
CD87), by binding its specific ligand uPA at the cell surface
allows the conversion of plasminogen into plasmin with the
consequent degradation of the extracellular matrix. UPAR is a
heterogeneously glycosylated protein of 45–55 kDa, inserted
into the external leaflet of the plasma membrane through a
glycosylphosphatidylinositol (GPI) anchor [4]. UPAR is able to
activate different signal transduction pathways inside the cell,
events that are dependent on uPA binding, but in some cases
independent of the catalytic activity of uPA [5]. Since uPAR
lacks a transmembrane domain, the signalling events triggered
after uPA binding might be explained considering that uPAR
can interact with other proteins either directly or as part of a
multiprotein complex. Among the proteins that associate with
uPAR, integrins, FPRL1 (a homologue of the fMLP receptor,
FPR), LRP-1 (low-density lipoprotein–receptor-related pro-
tein), EGF-R (Epidermal Growth Factor Receptor), caveolin-1,
and vitronectin can be mentioned. Through these associations
uPAR can modify the state of the cell, controlling cell adhesion,
migration and proliferation [5].
As other GPI-anchored proteins, uPAR is enriched in lipid
rafts [6,7]. Lipid rafts or lipid membrane microdomains have
been biochemically characterized by their resistance to
solubilization with non ionic detergents at low temperatures
[8,9]. These conditions lead to the isolation of detergent-
resistant membranes (DRM), which have been extensively used
in order to study lipid raft composition and function. DRMs are
highly enriched in cholesterol and sphingolipids, such as
sphingomyelin, ceramide and glycosphingolipids [8,10,11].
Because of their composition, lipid rafts are more ordered and
less fluid than other regions of the plasma membrane [8,12].
These lipid membrane microdomains are also typically
enriched, temporarily or permanently, in some proteins. These
include integral membrane proteins, such as caveolins, flotillins
and VIP36, GPI-anchored proteins like PLAP and Thy-1, some
transmembrane proteins such as growth factor receptor tyrosine
kinases, and signalling effectors such as G proteins and Src-
family tyrosine kinases [13,14]. Lipid rafts have been involved
in signal transduction events, vesicular trafficking, protein
sorting and entrance of intracellular pathogens [13–16].
No information is available concerning the biochemical
nature of uPAR environment within lipid rafts. The aim of this
study was to identify and characterize the lipid rafts in which
uPAR is located at steady-state conditions, i.e. in the absence of
its extracellular ligand uPA. We also wanted to investigate
whether the cell membrane microenvironment in which uPAR is
located is modified after receptor activation by its ligand uPA (or
ATF, the amino terminal, proteolytically inactive fragment of
uPA). In this paper we analyze some aspects of the lipid com-
position of membrane fractions immunoprecipitated with a
specific anti uPAR antibody, from a detergent-resistant, cho-
lesterol- and sphingolipid-enriched membrane fraction preparedfrom epithelial cells. We demonstrate that uPAR is partially
associated to the detergent-resistant membranes (DRM) ob-
tained from HEK293-uPAR cells, and that after uPA binding
there is a 3-fold increase in uPAR association to the DRM. We
also show that uPA or ATF binding enrich the cell membrane
microenvironment in which uPAR is located of sphingomyelin
and gangliosides, while depleting it of neutral glycosphingoli-
pids. The functional relevance of the presence of uPAR in lipid
microdomains is shown by the complete inhibition of uPA
intracellular signalling in methyl-β-cyclodextrin (CD)-treated
cells in which lipid rafts are disrupted. We conclude that uPAR is
located in specific subdomains within lipid rafts, the composi-
tion of which as well as uPAR distribution in the plasma cell
membrane is regulated by its ligand uPA.
2. Materials and methods
2.1. Materials
Cell culture media and supplements were purchase from Gibco-BRL
(Carlsbad, CA, USA) and plastic ware was from Costar (Cambridge, MA,
USA). Triton X-100, methyl-β-cyclodextrin and general laboratory chemicals
were from Sigma-Aldrich (St. Louis, MO, USA). Secondary HRP-conjugated
antibodies and Redivue L-[35S]methionine were from Amersham Pharmacia
Biotech (Buckinghamshire, UK). PVDF membranes were from Millipore (MA,
USA). Chemoluminescent substrate was from Pierce (IL, USA). Clinical grade
uPAwas obtained from Crinos (Italy). The R4 anti-uPAR antibodies were kindly
provided by Dr. Gunilla Høyer-Hansen (Finsen Laboratory, Copenhagen,
Denmark). The polyclonal anti-uPAR antibodies as well as ATF (the Amino
Terminal Fragment of uPA) were produced and tested in our laboratory [6]. The
monoclonal antibodies to Transferrin Receptor were purchased from Zymed
Laboratories (S. San Francisco, CA, USA). The rabbit polyclonal antibodies to
Caveolin-1 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA,
USA). The rabbit polyclonal antibodies to Phospho-p44/42 MAP Kinase were
purchased from Cell Signalling Technology, Inc. (Danvers, MA, USA), while the
rabbit polyclonal antibodies to total ERK were from Santa Cruz Biotechnology,
Inc. Protein G-Sepharose beads were from Amersham Pharmacia Biotech
(Buckinghamshire, UK). Protein G-coupled magnetic beads (Dynabeads) were
from Dynal ASA (Smestad, Oslo, Norway). Sphingosine was prepared from
cerebroside [40]. [1-3H]sphingosine was prepared by specific chemical oxidation
of the primary hydroxyl group of sphingosine followed by reduction with sodium
boro[3H]hydride [41] (radiochemical purity over 98%; specific radioactivity 2 Ci/
mmol). Tritiated lipids were extracted from [1-3H]sphingosine-fed cells, purified,
characterized and used as chromatographic standards. Sphingolipids and
glycerolipids to be used as standards were extracted from rat brain, purified and
characterized [42].
2.2. Cell culture
HEK293 cells stably transfected with human uPAR were cultured in
Dulbecco's Modified Eagle Medium supplemented with penicillin (100 U/ml),
streptomycin (100 U/ml), glutamine (5 mM), G418 (0.8 mg/ml) and 10% fetal
bovine serum at 37 °C in 5% CO2.
2.3. Metabolic radiolabeling
HEK 293-uPAR cells were incubated with 3.7×10−8 M [1-3H]sphingosine
(16 ml/162 cm2 flask) in culture medium for 2 h. After the pulse, medium was
replaced with fresh culture medium without radioactive sphingosine and cells
were chased for 48 h. Under these conditions, all sphingolipids (including
ceramide, sphingomyelin, neutral glycolipids and gangliosides) and phos-
phatidylethanolamine (obtained by recycling of radioactive ethanolamine
formed in the catabolism of [1-3H] sphingosine) are metabolically radiolabelled
[43].
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medium for 2 h and subsequently incubated in the presence of 17 μCi/ml L-[35S]
methionine for 20 h.
2.4. Purification of detergent-resistant membranes (DRM)
HEK 293-uPAR cells were plated at 70% confluence and lipids and proteins
were metabolically radiolabelled with [1-3H]sphingosine or L-[35S]methionine,
respectively, as described above. After metabolic radiolabeling, cells were washed
twicewith cold PBS, collected by scraping and centrifuged 5min at 1200 rpm.Cells
were lysed for 30 min on ice in ice-cold buffer A (150 mM NaCl, 2 mM EDTA,
50 mM Tris–HCl, pH 7.5) containing 1% TX-100 and a cocktail of proteinase
inhibitors (Complete, Roche, Basel, Switzerland). Cell lysates were centrifuged at
4 °C for 5 min at 1200×g. One ml of this postnuclear supernatant was brought to
40% sucrose using 80% sucrose in buffer A plus detergent, placed at the bottom of a
ultracentrifuge tube (Beckman Instruments Inc, Fullerton, CA, USA ) and overlaid
with 4 ml of 30% sucrose and 2 ml of 5% sucrose in buffer A plus detergent, and
filled up with 4 ml of buffer alone. Samples were centrifuged at 4°C for 17 h at
39,000 rpm (Beckman ultracentrifuge rotor SW41Ti). After centrifugation, 1 ml
fractions were collected from the top to the bottom of the gradient using a pipette.
Eight fractions were collected. Fractions 2 and 3 were determined to correspond to
DRM and fractions 7 and 8 to detergent soluble material (DS).
The sucrose density fractions obtained were analyzed to determine the protein
distribution (by running the same fraction volume in SDS-PAGE followed by
immunoblotting) as well as the content and distribution of radiolabelled lipids as
described below.
2.5. Analysis of protein patterns
Cell lysates and sucrose gradient fractions obtained after labelling cells with
[35S]methionine were analyzed to determine protein content and pattern. Similar
volumes of each sucrose density fraction were subjected to SDS-PAGE on 10%
acrylamide gels followed by immunoblotting.
2.6. ERK phosphorylation
To perform time course analysis, HEK293-uPARcells (80%confluence)were
serum-starved for 16 h and then incubated with 10 nM uPA for the indicated times
at 37 °C. Then cells were washed with cold PBS and lysed with 1× Laemmli
sample buffer (100 μl per well of 12-wells plate). After scraping, the extracts were
forced back and forward through a narrow gauge needle, microcentrifuged, and
incubated for 5 min at 95 °C. The samples were then subjected to SDS-PAGE on
10% acrylamide gels followed by immunoblotting.
For the disruption of lipid rafts, cells were pretreated for 30 min at 37 °C with
10 mM methyl-β-cyclodextrin [6]. Subsequently, cells were treated for 5 min at
37 °C with either medium alone, uPA 10 nM, or 10% bovine fetal serum, in the
absence or presence of 10 mM methyl-β-cyclodextrin. Then cells were treated as
mentioned above.
2.7. Immunoprecipitation experiments
To analyse specific lipid composition, pools of 600 μl from fractions 2+3
(DRM) and 7+8 (DS) obtained from the [1-3H]sphingosine labelled cell lysates
were precleared with Dynabeads-protein G for 2 h and then subjected to
immunoprecipitation with a monoclonal anti uPAR antibody (R4) that had been
precoupled to Dynabeads-protein G, overnight at 4 °C. Parallel experiments were
made with non-reactive mouse IgG as negative control. After washing 3 times with
lysis buffer, lipids were extracted from the immunoprecipitates with chloroform/
methanol 2:1 (v/v) and analyzed as described below. Proteins were eluted from the
beads with sample buffer under denaturating conditions, and subjected to SDS-
PAGE and immunoblotting for uPAR detection.
To quantitate uPAR in the various fractions, pools of 600 μl from fractions 2+3
(DRM) and 7+8 (DS) obtained from the [35S]-methionine labelled cell lysateswere
precleared with Sepharose-protein G for 2 h and then subjected to immunopre-
cipitation with a monoclonal anti uPAR antibody (R4) that had been precoupled to
Sepharose-protein G, overnight at 4 °C. Parallel experiments were made with non-
reactive mouse IgG as negative control. After washing 3 times with lysis buffer, theamount of radioactivity present in the immunoprecipitate was determined. Then,
the samples were subjected to SDS-PAGE and autoradiography.
2.8. Analysis of radioactive lipids
The cell lysate, post-nuclear supernatant and sucrose gradient fractions
obtained after [1-3H]sphingosine cell metabolic radiolabeling were analyzed to
determine the content of radiolabelled lipids [12]. Sampleswere dialyzed for 3 days
against distilled and decarbonated water. Then, samples were lyophilized, and
lipids were extracted twice with 0.5 ml chloroform/methanol 2:1 (v/v) [26].
Aliquots of the lipid extracts were analyzed by HPTLC as described below, fol-
lowed by radioactivity imaging for quantification. Identity of lipids separated by
HPTLC was assessed by co-migration with purified molecular standards.
2.9. Thin layer chromatography
Tritiated lipids were separated by one-dimensional HPTLC carried out with
the solvent systems chloroform/methanol/0.2% aqueous CaCl2 55:45:10 v/v/v,
followed by radioactivity imaging for quantification of radioactivity. In some
cases, lipids were also separated by two-dimensional HPTLC, using chloroform/
methanol/water, 110:40:6 (v/v/v) as the solvent system for the first run, and
chloroform/methanol/0.2% aqueous CaCl2, 55:45:10 (v/v/v) for the second run.
Cholesterol in the lipid extracts was separated by one-dimensional HPTLC
using the solvent system hexane/ethyl acetate, 3:2 (v/v). Cholesterol was
quantified after separation on HPTLC by visualization with 15% concentrated
sulphuric acid in 1-butanol.
2.10. Other analytical methods
The protein content was determined according to Lowry [44], or with themicro
BCA assays (Pierce Chemical Co.), using bovine serum albumin in the presence of
sucrose as the reference standard.
The radioactivity associated with whole cells, cell fractions, immunoprecip-
itation samples, lipids and delipidized pellets was determined by liquid scintillation
counting.Digital autoradiography of theHPTLCplateswas performedwith aBeta-
Imager 2000 instrument (Biospace, Paris) using an acquisition time of about 24 h.
The radioactivity associatedwith individual lipidswas determinedwith the specific
β-Vision software provided by Biospace.3. Results
3.1. UPAR is enriched in detergent-resistant membranes obtained
from HEK 293-uPAR cells
It has been previously reported that uPAR can be isolated from
cell membranes in association with Triton X-100-resistant low-
density membranes [6,7]. As a first approach to identify and
characterize the plasma membrane domains in which uPAR is
located, we used HEK 293-uPAR cells that do not produce uPA,
performed sucrose density gradients on theTritonX-100 (TX-100)
extract and analyzed uPARassociationwithDRM, i.e. fractions 2–
3 of the gradient, and DS (detergent-soluble material, i.e. fractions
7–8).
We first compared the distribution of total proteins and uPAR
in the different fractions of sucrose density gradients. HEK 293
cells, stably transfected with human uPAR (HEK293-uPAR,
[6]) were incubated in methionine-free medium for 2 h and
subsequently supplemented with 17 μCi/ml L-[35S]methionine
for 20 h. After metabolic radiolabeling, cells were lysed in 1%
TX-100 and then the lysates were subjected to ultracentrifuga-
tion on sucrose gradients and separated into 8 fractions.
Fractions were counted for 35S content and analyzed by SDS-
Fig. 1. uPAR associates with DRM. Cells were lysed in the presence of TX-100 at 4 °C. DRMwere purified by sucrose gradient centrifugation as described in material
and methods. One ml fractions were collected from the top (fraction 1) to bottom (fraction 8). Panel A: proteins were analyzed by SDS-PAGE and Western blotting
using specific anti-uPAR, anti-caveolin-1 and anti TfR antibodies, respectively. Upper panel: control cells. Middle panel: cells treated with 10 nM uPA for 5 min at
37 °C. Lower panel: cells treated with 10 nM ATF for 5 min at 37 °C. Data are representative of 3 independent experiments. Panel B: in control cells, metabolic
labelling of cell proteins with [35S]methionine was performed before DRM separation. The amount of protein-associated radioactivity was determined by liquid
scintillation counting. Data are expressed as percentage of total radioactivity present in the lysate. Panel C: DRM and DS were obtained by sucrose gradient
centrifugation from control (untreated) cells and subjected to immunoprecipitation performed at 4 °C using anti-uPAR antibodies. Non-reactive IgG were used as
negative control. Samples were separated by SDS-PAGE and then transferred on a PVDF membrane. [35S]methionine-labelled cell proteins immunoprecipitated with
anti-uPAR antibodies or non-reactive IgG were detected by autoradiography. The band corresponding to uPAR is indicated with an arrow.
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uPAR was present in the DRM (lanes 2 and 3), which contained
less than 1% of the total [35S]proteins (Fig. 1B). Caveolin-1, in
fact showed a similar distribution. On the other hand, TfR
partitioned exclusively in the DS membrane fractions of the
gradient, which also contained the majority of uPAR (Fig. 1A,
Upper Panel, lanes 6–8). Besides, the DS fractions contained
more than 70% of the total cell protein radioactivity (Fig. 1B).
Immunoprecipitation of uPAR from the DRM and DS fractions
isolated from L-[35S]-methionine labelled-cells (Fig. 1C, arrow)
and counting of the precipitated radioactivity showed that uPAR
was highly enriched in these fractions (close to hundred fold),
while constituting only 0.03% of the total proteins (Table 1).
The heterogeneous glycosylation pattern and the presence
of both full-length and truncated forms (D2D3 forms) of
uPAR, account for the double, enlarged and fuzzy band of
Fig. 1C [4,5].3.2. UPA binding increases uPAR association to
detergent-resistant membranes independently of its catalytic
activity
It has been widely described that uPA binding to uPAR
induces both proteolysis-dependent and independent intracel-
lular signalling events that affect adhesion, migration, and
proliferation in a variety of cells [5]. Here, we studied whether
uPA plays a role in uPAR localization to lipid rafts. HEK 293-
uPAR cells were incubated either with 10 nM uPA or ATF (the
Amino Terminal Fragment of uPA that binds to the receptor but
lacks the catalytic domain) for 5 min at 37 °C, enough to
saturate cell surface uPAR [5] and to induce intracellular
signalling (see below). After the incubation period, cells were
lysed in 1% TX-100 and treated as described above.
Interestingly, after uPA binding there was a three-fold increase
in uPAR content in the DRM (i.e. from about 5% to about 15%,
Fig. 2. Disruption of lipid rafts abolishes uPA-induced ERK phosphorylation.
(A) HEK 293-uPAR cells were serum-starved for 16 h and then treated with
10 nM uPA at 37 °C for the indicated times. Phosphorylated and total ERK were
detected by immunoblot analysis. The Western blots are representative of three
independent experiments. (B) HEK 293-uPAR cells were serum-starved for 16 h
and then pre-treated with 10 mM CD at 37 °C. After 30 min, cells were
incubated for another 5 min at 37 °C with 10 nM uPA, 10% FBS, or medium
alone, in the absence or presence of 10 mM CD, as indicated. Phosphorylated
and total ERK were detected as described in Materials and methods.
Table 1
Distribution of 35S radioactivity after immunoprecipitation with anti-uPAR or non specific (control) IgG in DRM and DS fractions
Material Antibodies Input IP a Preclear Supernatant uPAR enrichment (%) b
DRM IgG anti 7567
uPAR non-reactive 128767 (5.15%, sp.) 1639 109700 85.8
DRM IgG 128767 991 1411 112567 NP
IgG anti 44898
DS uPAR non-reactive 5473752 (0.06%, sp.) 22022 5389167 1
DS IgG 5473752 12018 25800 5426897 NP
Cell proteins were previously metabolically labelled with [35S]-methionine. Data are expressed in cpm unless specified. The [35S]-methionine uptake by the cells was
of 21,920,000 cpm in total , which is considered as 100% of total cell proteins; of this about one quarter was used in this specific experiment. In additional experiments,
the same results were obtained.
a The percent uPAR after immunoprecipitation is calculated after subtraction of the non specific (pre-clear), and indicated with “sp”.
b The fold enrichment of uPAR is calculated by dividing the percent of specific uPAR precipitated from DRM divided by the percent precipitated from the DS fraction.
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maintained the same distribution pattern (Fig. 1A). An increase
in uPAR association to DRM is also observed after ATF
binding, suggesting that this event is independent of the
catalytic activity of uPA (Fig. 1A, lower panel, lanes 2 and 3).
3.3. Disruption of lipid rafts completely prevents uPA/uPAR
intracellular signalling
To investigate the relevance of uPAR localization in lipid
microdomains we tested the rate of ERK phosphorylation in
conditions in which we previously demonstrated that lipid rafts
are disrupted, and uPAR is found exclusively in the DS
membrane fractions (not shown, but see [6]). First, we analyzed
the rate of ERK phosphorylation induced by uPA at different
time points. As shown in Fig. 2A, uPA induces ERK
phosphorylation within 1 min. This activation is transient,
since the phosphorylated ERK returns to basal levels in less
than 15 min. Then, we compared the rate of ERK phosphor-
ylation induced by uPA in untreated or 10 mM CD-treated
HEK293-uPAR cells. Under the last condition uPAR is found
exclusively in the DS membrane fractions (not shown and [6]).
Stimulation with serum, another inducer of ERK that does not
act through uPAR, was used as control. As shown in Fig. 2B,
uPA induced ERK phosphorylation in untreated cells after
5 min of incubation, whereas CD-treatment prevented ERK
phosphorylation altogether. Unlike uPA, the treatment of cells
with CD had no effect on the serum-induced ERK phosphor-
ylation (Fig. 2B). This result is also in agreement with pre-
viously reported data on the same cells in which CD treatment
specifically blocked uPAR-dependent, but not integrin-depen-
dent, adhesion on vitronectin [6]. Thus, we conclude that the
presence of uPAR in lipid microdomains is relevant for its sig-
nalling function. On these premises, we have decided to analyze
the lipid composition of the uPAR-containing microdomains
and test whether uPA binding would induce any change in the
lipid microdomains.
3.4. UPAR associates with sphingolipid and cholesterol-enriched
detergent-resistant membranes
To characterize the lipid composition of uPAR membrane
microdomain, sphingolipids were metabolically labelled with[1-3H]sphingosine. [1-3H]sphingosine is rapidly taken up by
cultured cells and is efficiently converted into complex
sphingolipids. Moreover, it is in part catabolized to tritiated
ethanolamine, that is recycled for the biosynthesis of phospha-
tidylethanolamine (PE), a glycerophospholipid that can be
conveniently used as a marker of non-DRM fractions [12,17].
After metabolic radiolabeling, cells were first incubated with
10 nM uPA or ATF for 5 min at 37 °C and then lysed in 1% TX-
100. The lysates were subjected to ultracentrifugation on su-
crose gradients and separated into 8 fractions. The radioactive
lipids were extracted, separated by HPTLC and analyzed
by radioimaging. The radioactive lipid patterns of the gradient
fractions and the quantitative distribution of radioactive sphingo-
lipids and PE are not shown but are available in Suppl. Figure 1.
No statistically significant differences were observed between
cells incubated with medium alone, uPA or ATF. The DRM
fractions contained about 25% of cellular sphingolipids (25.3 and
24.8% for control and uPA-treated, 20.6% for ATF-treated cells),
in particular sphingomyelin (the major SL present in these cells),
ceramide, LacCer, GM2 and GM3, and other minor SL. PE, as
Table 2
Distribution of [3H] radioactivity after immunoprecipitation with anti-uPAR or
non-reactive (control) IgG in sphingolipid-enriched membrane fractions of
control, or uPA/ATF treated cells
Material Addition Input IP a Preclear % [3H] sp
precipitated b
Anti uPAR none 17812 1621.5 0 8.8
Non-reactive IgG none 17812 54.4 11.9
Anti uPAR uPA 14875.5 1441 46.8 9.2
Non-reactive IgG uPA 14875.5 72.5 0
Anti uPAR ATF 17873.5 2026.5 33.1 11.2
Non-reactive IgG ATF 17873.5 60.4 0.9
Cell lipids were previously metabolically labelled with [3H]-sphingosine. Data
are expressed in dpm unless specified.
a The immunoprecipitate was performed with the R4 antibody or with a non-
reactive isotypic control.
b The percent of input radioactivity is calculated after subtraction of the
amount precipitated from the non reactive IgG.
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gradient (Suppl. Figure 1). The other major lipid component of
membrane lipid domains is cholesterol. Thus, we also checked the
distribution of cholesterol in the gradient. Again, about 25% of
total cellular cholesterol was found in DRM independently of the
presence of uPAR ligands (Suppl. Figure 1). These results
demonstrate that binding of uPA or ATF does not lead to an
overall modification of the lipid composition of the DRM.
3.5. UPA binding modifies the lipid composition of uPAR
membrane microdomain independently of its catalytic activity
Since uPAR associates to lipid rafts, and this association is
increased after uPA binding, we determined the sphingolipid
content of the uPAR membrane microdomains at steady state
and after uPA binding. For this purpose, pooled DRM fractions
(fractions 2 and 3) from the sucrose density gradients shown in
Fig. 1 and Suppl. Figure 1 were subjected to immunoprecip-
itation with the anti-uPAR monoclonal antibody R4, under
conditions designed to preserve the integrity of the domains (see
Methods section) [18]. We also used non-reactive IgG as a
negative control. By Western blot assays we determined that the
immunoprecipitates performed with R4 contained the uPAR
associated to DRM (Fig. 3). In control, uPA, and ATF-treated
cells, uPAR was present in both the full length and the cleaved
(D2D3) forms. However, no uPAR was found in the precipitate
with non-reactive IgG. The presence of D2D3 form is in
keeping with the higher sensitivity of DRM-uPAR (as opposed
to DS-uPAR) to cleavage by uPA or other endogenous protease
[6].
The specific (R4 antibody) immunoprecipitate contained
about 10% (from 8.8 to 11%) of the total tritium labelled
sphingolipids associated to DRM, in the three conditions tested
(control, uPA- or ATF-treated, Table 2). Less than 0.5% of the
total tritium labelling was associated with the non-reactive IgG
and with the protein G-coupled magnetic beads used to preclear
the samples (Table 2). No uPAR was detected with the protein
G-coupled magnetic beads alone (not shown). The recovery was
higher than 85% in all the samples.
It is worth mentioning that when the DS fractions obtained
from the sucrose density gradients of Fig. 1 and Suppl. Figure 1
were subjected to immunoprecipitation with the antibody R4,
uPAR was effectively precipitated, but the immunoprecipitatesFig. 3. Immunoprecipitation of uPAR from the DRM. DRM was prepared by
sucrose gradient centrifugation from control cells (left), cells treated with 10 nM
uPA (middle) or with 10 nM ATF (right) for 5 min at 37 °C, and subjected to
immunoprecipitation performed at 4 °C using anti-uPAR antibodies (lane 1). Non-
reactive IgGwere used as negative control. Sampleswere separated by SDS-PAGE
and then transferred on a PVDF membrane. uPAR was visualized by Western
blotting with specific antibodies.contained less than 2% of the radioactive lipids present in the
DS fractions, mainly represented by PE (data not shown).
Tritiated lipids extracted from the uPAR immunoprecipitates
were analyzed by two-dimensional HPTLC and compared to
those from theDRM (Fig. 4). TheDRM from cells incubatedwith
medium alone, uPA or ATF contained sphingomyelin, ganglio-
sides GM2 and GM3, neutral glycosphingolipids GlcCer and
LacCer, and ceramide (Fig. 4A, left panel). The two-dimensional
lipid patterns of the DRM in control, uPA- and ATF-treated cells
were very similar. Moreover, the lipid composition of the uPAR
immunoprecipitate in control cells did not significantly differ
from that of the total DRM (Fig. 4A, upper panel). However, in
the uPAR immunoprecipitates from both uPA- and ATF-treated
cells (Fig. 4A, middle and lower panels), we found a much lower
amount of neutral glycosphingolipids, which remained in the
supernatant. After quantitative determination of the radioactivity
associated with each spot, we found a 60% reduction in neutral
glycosphingolipids in the uPAR immunoprecipitates from both
uPA- and ATF-treated cells (Fig. 4B). In these same immunopre-
cipitates, we found a 1.5 fold increase inGM2 andGM3 (Fig. 4B).
These results suggest that uPA binding modifies the lipid
composition of uPAR membrane microdomains, and that this
modification is independent of the catalytic activity of uPA.
4. Discussion
UPAR is a GPI anchored protein that can promote signal
transduction events inside the cell independently of the catalytic
activity of uPA [5]. The intracellular signalling process may be
triggered by the association of uPAR to other proteins such as
vitronectin [20], integrins [21], FPRL1 [22], caveolin-1 [7,19],
EGF-R (Epidermal Growth Factor Receptor) [23] and LRP-1
(low-density lipoprotein–receptor-related protein) [24]. Since
uPAR is located in different compartments at the cell surface, the
microenvironment, i.e., the surrounding lipids and proteins, should
be important to control uPAR function.UPAR, asmany other GPI-
anchored proteins [15,25], is partially localized in lipid rafts or
lipid membrane microdomains, zones of the membrane particu-
larly enriched in cholesterol and sphingolipids, being therefore
partially insoluble in TX-100, and sensitive to cholesterol
Fig. 4. Sphingolipid composition of uPARmembrane microdomain. (A) Two-dimensional HPTLC patterns of radioactive lipids present in uPAR immunoprecipitates from
DRM. Cell lipids were metabolically labelled with [1-3H]sphingosine, (2 h pulse followed by 48 h chase). DRM were prepared by sucrose gradient centrifugation from
control cells, cells treated with 10 nM uPA or with 10 nM ATF for 5 min at 37 °C, and subjected to immunoprecipitation performed at 4 °C using anti-uPAR antibodies.
Radioactive lipids from DRM and from anti uPAR immunoprecipitates were extracted and separated by 2D-HPTLC using the solvent systems: 1st run, chloroform/
methanol/water, 110:40:6 by vol; 2nd run, chloroform/methanol/0.2% aqueous CaCl2, 50:42:11 by vol. Radioactive lipids were detected by digital autoradiography; 500–
2000 dpm/plate; time of acquisition: 65 h. Upper panel: control cells. Middle panel: cells treated with 10 nM uPA for 5 min at 37 °C. Lower Panel: cells treated with 10 nM
ATF for 5 min at 37 °C. Right panel: total DRM (input). Left panel: anti uPAR immunoprecipitates. Patterns are representative of those obtained in three different
experiments. (B) Quantitative analysis of the lipid composition in the anti-uPAR immunoprecipitated microdomain. The amount of radioactivity associated with each spot
shown in Awas determined with the specificβ-Vision software provided byBiospace. The data are expressed as percent of total 3H radioactivity present in the plates for the
three conditions tested (control, 10 nM uPA or 10 nM ATF).
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insolubility in TX-100, since a chimeric uPAR mutant, bearing
the EGFR transmembrane domain in place of its GPI anchor
consensus sequence, does not partition to lipidmembrane domains
[6].
Lipid and protein organization at the cell surface is considered
to play a crucial role in modulating functional processes, such as
those associated with uPAR, and favouring their compartmental-
ization. This idea is supported by our experiments with CD.
Indeed, after CD treatment, lipid rafts are disrupted and the uPA-
dependent induction of ERK phosphorylation is completely
inhibited. This is a specific effect for the uPA/uPAR system, since
other signals that do not go via lipid rafts are insensitive to CD
(Fig. 2). The specific adhesion of HEK239-uPAR cells onto
vitronectin was also reported to be totally dependent on lipid
microdomains integrity [6]. These data confirm the expected
importance of lipid rafts in uPAR intracellular signalling. How-
ever, no data were available concerning the lipid composition of
uPAR environment in lipid rafts. Our results show that in
HEK293-uPAR cells, uPAR is partially associated to DRM, and
that the association to DRM increases after ligand binding. In the
absence of ligand, uPAR is located in a lipid environment very
similar to that of total DRM, enriched in sphingomyelin and
glycosphingolipids. However, after treatment of cells with uPA or
ATF the specific lipid environment is impoverished of neutral
glycosphingolipids with relative increases of sphingomyelin and
gangliosides (Fig. 4).
Although many receptors are localized in lipid rafts, the effect
of the ligand in this association is highly variable. For example,
the insulin receptor is recruited to lipid rafts after insulin binding
[27], while the β2-adrenergic receptor moves out of lipid rafts
after agonist binding [28]. However, the functional implications
of such changes in receptor compartmentalization are unclear. In
our system, even if uPAR is already localized in lipid
microdomains, more receptor is recruited into lipid rafts in the
presence of its specific ligand uPA. A similar increase of uPAR
association to lipid rafts is observed after ATF binding. SinceATF
binds to the receptor but lacks the catalytic activity, it is the
binding of uPA to uPAR but not the associated cell surface
proteolysis that is required for receptor recruitment into lipid rafts.
Moreover, the microenvironment of the lipid rafts in which uPAR
is located changes after ligand binding. It has been proposed that
by modulating the entrance of some proteins, lipid rafts can
control intracellular signalling [16]. In this sense, increasing the
amount of uPAR in lipid rafts after uPA binding might trigger or
enhance the uPA/uPAR-related signalling activation that control
cell adhesion, migration, proliferation and differentiation. Here
we showed that the presence of uPAR in lipid rafts is essential for
uPA/uPAR-induced ERK phosphorylation. Previously, it has
been shown that the localization of uPAR and uPA in caveolae
enhances pericellular plasminogen activation [7]. Other data
show that dimeric uPAR partitions preferentially to lipid rafts,
where it binds to vitronectin in a way that can be blocked
by cholesterol depletion [6]. While uPA binds to uPAR inde-
pendently of its membrane localization and dimerization status,
uPA-induced uPAR cleavage is strongly accelerated in lipid rafts
[6].Our results support the idea that a protein can belong to
distinct lipid membrane domains, since the SL microenviron-
ment in which uPAR is located changes after uPA binding. In
fact it has been reported that after certain stimuli, uPAR can
segregate at the leading edge of a migrating T-cell in GM3-
enriched lipid rafts rather than GM1-enriched lipid rafts
localized at the uropod [29]. In addition to the specific lipid
composition changes induced by the ligands, we also find by
confocal fluorescence and co-immunoprecipitation experiments
(not shown) that uPAR does not co-localize with caveolin-1 in
the plasma membrane of HEK293-uPAR cells. In fact, co-
localization between uPAR and caveolin is found only in the
Golgi (Cortese et al., in preparation). This finding also elimi-
nates any doubt that the DRM fractions that we have analyzed
may contain not only plasmamembrane but also Golgi and other
organelles membranes.
After receptor activation by ligand binding, the uPAR-
immunoprecipitate was enriched in gangliosides and sphingo-
myelin. Gangliosides are found in the outer layer of the plasma
membrane and are involved in a number of biological processes
such as cell adhesion, signal transduction, tumorigenesis, dif-
ferentiation and metastasis [30,31]. As one of the gangliosides
enriched in the uPAR-immunoprecipitate was GM3, it could be
speculated that the GM3 enrichment after uPA binding might be
relevant in the role that uPAR plays in cell processes as GM3 is
involved in cell motility/invasiveness [32] and EGFR dimer-
ization and autophosphorylation [33–36]. This might be
relevant since, as mentioned before, EGFR and uPAR can
modulate each others activity [23,37]. However, additional
studies are required to understand the functional role of GM3
enrichment in lipid raft under cellular events regulated by
the uPA/uPAR system. This result is intriguing since the
generation of the second messenger ceramide from SM has
been suggested to occur preferentially in lipid rafts upon certain
stimuli. On a speculative basis, this local change in the SL
content may modify raft functioning, triggering signalling
events and allowing receptor oligomerization [38,39]. In addi-
tion, we found that neutral glycosphingolipids were diminished
in the uPAR-enriched lipid rafts. According to these results, it
could be hypothesized that neutral glycosphingolipids might
restrict the presence of uPAR in lipid rafts from resting cells.
Again, additional studies are required in order to test this
hypothesis.
Altogether, these results suggest that uPAR is located in
specific subdomains within lipid rafts, with characteristic lip-
id composition. The localization of the receptor as well as the
composition of the subdomains is regulated by ligand binding.
Hypothetically, this microenvironment might modify uPAR
specific responses. Neutral glycosphingolipids might restrict
the presence of uPAR in lipid rafts, while SM and ceramide
could induce intracellular signalling cascades, and GM2 and
GM3 might facilitate the association with other receptors
and signalling molecules. Our findings shed light not only
in the relevance of the localization of uPAR in lipid rafts,
but also show the important role that lipid rafts them-
selves play in the selectivity and compartmentalization of cell
processes.
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